BioHarvest Sciences (NASDAQ:BHST - Get Free Report) will likely be announcing its earnings results before the market opens on Monday, March 31st. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $7.24 million for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
BioHarvest Sciences Stock Down 4.4 %
Shares of NASDAQ BHST traded down $0.30 during mid-day trading on Thursday, reaching $6.45. The company's stock had a trading volume of 4,606 shares, compared to its average volume of 8,197. BioHarvest Sciences has a 52 week low of $6.27 and a 52 week high of $7.38. The company has a market cap of $105.94 million, a price-to-earnings ratio of -5.16 and a beta of 2.27. The firm's fifty day simple moving average is $5.63.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on BHST. HC Wainwright began coverage on BioHarvest Sciences in a research report on Friday, December 6th. They set a "buy" rating and a $14.00 price objective on the stock. Maxim Group started coverage on BioHarvest Sciences in a research note on Wednesday, December 18th. They set a "buy" rating and a $12.00 price target on the stock.
Read Our Latest Stock Analysis on BHST
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Read More
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
